WO2010008203A3 - Preparation pharmaceutique contenant un inhibiteur des canaux calciques - Google Patents

Preparation pharmaceutique contenant un inhibiteur des canaux calciques Download PDF

Info

Publication number
WO2010008203A3
WO2010008203A3 PCT/KR2009/003897 KR2009003897W WO2010008203A3 WO 2010008203 A3 WO2010008203 A3 WO 2010008203A3 KR 2009003897 W KR2009003897 W KR 2009003897W WO 2010008203 A3 WO2010008203 A3 WO 2010008203A3
Authority
WO
WIPO (PCT)
Prior art keywords
calcium channel
channel blocker
active ingredient
pharmacologically active
pharmaceutical formulation
Prior art date
Application number
PCT/KR2009/003897
Other languages
English (en)
Korean (ko)
Other versions
WO2010008203A2 (fr
Inventor
김성욱
전성수
구자성
김진욱
이나영
Original Assignee
한올제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한올제약주식회사 filed Critical 한올제약주식회사
Publication of WO2010008203A2 publication Critical patent/WO2010008203A2/fr
Publication of WO2010008203A3 publication Critical patent/WO2010008203A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention concerne une préparation pharmaceutique contenant un inhibiteur des canaux calciques comme principe pharmacologiquement actif et un matériau à libération contrôlée, ainsi qu’une préparation pharmaceutique comprenant un compartiment à libération immédiate contenant un agent préventif de l’hépatite et un inhibiteur comme principe pharmacologiquement actif, ainsi qu’un compartiment à libération prolongée contenant un inhibiteur des canaux calciques comme principe pharmacologiquement actif. La préparation selon l’invention présente l’avantage : d’augmenter au maximum les effets de résistance à la pression pharmacologique et clinique et les effets de prévention des complications ; d’éviter une interaction avec les médicaments métabolisés par la même enzyme dans le foie ; et d’empêcher et d’inhiber l’hépatite d’origine médicamenteuse causée par un traitement médicamenteux au long cours.
PCT/KR2009/003897 2008-07-15 2009-07-15 Preparation pharmaceutique contenant un inhibiteur des canaux calciques WO2010008203A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080068746 2008-07-15
KR10-2008-0068746 2008-07-15

Publications (2)

Publication Number Publication Date
WO2010008203A2 WO2010008203A2 (fr) 2010-01-21
WO2010008203A3 true WO2010008203A3 (fr) 2010-04-15

Family

ID=41550843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/003897 WO2010008203A2 (fr) 2008-07-15 2009-07-15 Preparation pharmaceutique contenant un inhibiteur des canaux calciques

Country Status (2)

Country Link
KR (1) KR20100008356A (fr)
WO (1) WO2010008203A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082785A2 (fr) * 2009-01-16 2010-07-22 한올제약주식회사 Composition pharmaceutique orale
EP2804613A4 (fr) 2012-01-16 2015-12-09 Elizabeth Mckenna Compositions et méthodes utilisées pour traiter des maladies et des troubles hépatiques
KR101893110B1 (ko) * 2016-07-27 2018-08-31 삼일제약 주식회사 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제
KR102162921B1 (ko) 2018-11-28 2020-10-07 건양대학교 산학협력단 니페디핀 함유 나노입자를 포함하는 지방간 질환 및 인슐린 저항성 예방 또는 치료용 조성물
CN110038134B (zh) * 2019-05-31 2022-03-29 南开大学 用于肿瘤治疗的双响应性载抗肿瘤药物的纳米药物传递系统及制备方法
KR102414285B1 (ko) * 2020-06-02 2022-06-28 이화여자대학교 산학협력단 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물
CN114712319B (zh) * 2022-03-25 2024-01-09 北京诺康达医药科技股份有限公司 一种非洛地平盐酸普萘洛尔复方制剂及其制备方法
CN115381791B (zh) * 2022-09-21 2023-06-16 迪沙药业集团有限公司 一种盐酸氟桂利嗪药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022385A (ko) * 1997-08-29 2001-03-15 실버스타인 아써 에이. 암로디핀 및 스타틴 화합물을 포함하는 복합 조성물
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
KR20080018841A (ko) * 2006-08-24 2008-02-28 한올제약주식회사 방출성이 제어된 디히드로피리딘계 칼슘길항제/스타틴계지질저하제의 복합제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022385A (ko) * 1997-08-29 2001-03-15 실버스타인 아써 에이. 암로디핀 및 스타틴 화합물을 포함하는 복합 조성물
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
KR20080018841A (ko) * 2006-08-24 2008-02-28 한올제약주식회사 방출성이 제어된 디히드로피리딘계 칼슘길항제/스타틴계지질저하제의 복합제제

Also Published As

Publication number Publication date
WO2010008203A2 (fr) 2010-01-21
KR20100008356A (ko) 2010-01-25

Similar Documents

Publication Publication Date Title
WO2010008203A3 (fr) Preparation pharmaceutique contenant un inhibiteur des canaux calciques
WO2009134057A3 (fr) Formulation pharmaceutique contenant un agent bloquant les récepteurs de l'angiotensine ii
WO2008010921A3 (fr) Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques
MY173730A (en) Orally-disintegrating solid preparation
BRPI0513909A (pt) comprimido farmacêutico de camada múltipla para a liberação controlada de ingredientes ativos com solubilidade altamente dependente do ph
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
WO2007090882A3 (fr) Compositions pharmaceutiques
WO2006084474A3 (fr) Preparation pharmaceutique stable comprenant une dose fixe de fenofibrate et d'un inhibiteur de la hmg-coa reductase
WO2010056754A3 (fr) Inhibition de cible mammalienne de rapamycine
WO2011084593A3 (fr) Formulations empêchant un usage abusif
WO2009061607A3 (fr) Matières non miscibles à l'eau en tant que véhicules pour l'administration d'un médicament
WO2007143155A3 (fr) Forme pharmaceutique à liberation prolongée contenant de la phényléphrine
WO2008013710A3 (fr) Comprimé croquable contenant de la phényléphrine
WO2008000731A3 (fr) Composition pharmaceutique destinée à l'administration par voie orale d'acides gras polyinsaturés oméga et d'au moins un principe actif incompatible avec eux, et procédé de préparation de celle-ci
MX2009010556A (es) Formas de dosificacion modificada de tacrolimus.
WO2010066749A3 (fr) Comprimés d'ulipristal acétate
WO2009059701A3 (fr) Comprimés à libération prolongée contenant de l'hydromorphone
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
WO2005117895A3 (fr) Compositions contenant de la meloxicame
WO2009004082A3 (fr) Compositions pharmaceutiques anticonvulsives
WO2010048478A3 (fr) Comprimés et disques compartimentés avec deux médicaments ou plus pour libération à certains intervalles et à des vitesses spécifiques
WO2009034431A3 (fr) Formes posologiques à libération contrôlée de la varenicline
TW200806282A (en) Solid dosage formulations
WO2008084698A1 (fr) Composition pharmaceutique à libération entretenue de tacrolimus
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09798106

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09798106

Country of ref document: EP

Kind code of ref document: A2